Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-801 in Healthy Overweight and Obese Volunteers
NCT04561245Phase 1Completed
- Sponsor
- Altimmune, Inc.
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pemvidutide in obesity and Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Altimmune, Inc. Primary endpoints: Number of Participants with One or More Treatment-Emergent Adverse Events, Maximum observed concentration of ALT-801 at Day 26 and 3 more. Started Nov 2020; status: completed.
02
Drugs
pemvidutide
03
Conditions
obesityNonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04561245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561245.